Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Nervonik closes $52.5m Series B funding to advance PNS system
US-based medical device company Nervonik has secured $52.5m in Series B financing aimed at advancing its peripheral nerve stimulation (PNS) …
-
Oruka reports positive data from Phase IIa trial for plaque psoriasis
Oruka Therapeutics has reported positive interim data from the ongoing EVERLAST-A Phase IIa trial evaluating ORKA-001 in patients with moderate-to-severe …
-
FDA approves AstraZeneca’s Saphnelo for SLE
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for the subcutaneous self-administration of Saphnelo (anifrolumab-fnia) using …
-
Sun Pharma to acquire Organon for $11.75bn
Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash, …
-
BrioHealth secures FDA approval to launch BrioVAD system trial
BrioHealth Solutions has secured conditional approval from the US Food and Drug Administration (FDA) to initiate a clinical trial of …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Kyowa Kirin and Kura initiate Phase II trial of ziftomenib for AML
Kyowa Kirin and Kura Oncology have started a Japanese Phase II registrational study of oral menin inhibitor ziftomenib in adult …
-
First patient dosed in GE HealthCare’s Phase II/III LUMINA clinical trial
GE HealthCare has dosed the first patient in its international, multi-centre Phase II/III LUMINA clinical trial for the investigational manganese-based …
-
CatalYm doses first patient in Phase II/III VINCIT trial
CatalYm has commenced dosing the first subject in its Phase II/III VINCIT trial, assessing the safety and efficacy of its …
-
Cumberland to sell drug portfolio to Apotex for $100m
Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canadian pharmaceutical company Apotex for $100m in cash. Under …
-
FDA grants clearance for Philips’ Rembra scanning platform
Philips has received the US Food and Drug Administration (FDA) 510(k) clearance for its Rembra platform of scanning systems, which …
-
ModeX starts dosing in MDX2003 trial for B-cell lymphoma
OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for relapsed or refractory B-cell …
-
MSD teams up with Google Cloud on agentic AI transformation
Merck & Co (MSD) and Google Cloud have formed a multi-year partnership, investing up to $1bn, to advance agentic AI …
-
Artera’s prostate biopsy and breast cancer assays receive CE mark
Artera has secured CE marking under the European Union In Vitro Diagnostic Regulation (EU IVDR) for its ArteraAI prostate biopsy …
-
Roche reports Phase III METEOROID study results for MOGAD
Roche has reported new findings from the Phase III METEOROID trial of Enspryng (satralizumab) in adults and adolescents with myelin …
-
Health Canada approves Biocon’s two denosumab biosimilars
Biocon has received a Notice of Compliance from Health Canada for Bosaya (denosumab) and Vevzuo (denosumab), both biosimilars referencing Prolia …
